943 related articles for article (PubMed ID: 10713001)
1. Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin-containing regimens.
Yew WW; Chan CK; Chau CH; Tam CM; Leung CC; Wong PC; Lee J
Chest; 2000 Mar; 117(3):744-51. PubMed ID: 10713001
[TBL] [Abstract][Full Text] [Related]
2. Comparative roles of levofloxacin and ofloxacin in the treatment of multidrug-resistant tuberculosis: preliminary results of a retrospective study from Hong Kong.
Yew WW; Chan CK; Leung CC; Chau CH; Tam CM; Wong PC; Lee J
Chest; 2003 Oct; 124(4):1476-81. PubMed ID: 14555582
[TBL] [Abstract][Full Text] [Related]
3. [Treatment outcomes of multidrug-resistant tuberculosis--comparison between success and failure cases].
Shigetoh E; Murakami I; Yokosaki Y; Kurimoto N
Kekkaku; 2001 Dec; 76(12):723-8. PubMed ID: 11806128
[TBL] [Abstract][Full Text] [Related]
4. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
API Consensus Expert Committee
J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
[TBL] [Abstract][Full Text] [Related]
5. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
[TBL] [Abstract][Full Text] [Related]
6. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ
Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of kanamycin, ethionamide, PAS and cycloserine in multidrug-resistant pulmonary tuberculosis patients.
Prasad R; Verma SK; Sahai S; Kumar S; Jain A
Indian J Chest Dis Allied Sci; 2006; 48(3):183-6. PubMed ID: 18610675
[TBL] [Abstract][Full Text] [Related]
8. Plasma drug activity in patients on treatment for multidrug-resistant tuberculosis.
Mpagama SG; Ndusilo N; Stroup S; Kumburu H; Peloquin CA; Gratz J; Houpt ER; Kibiki GS; Heysell SK
Antimicrob Agents Chemother; 2014; 58(2):782-8. PubMed ID: 24247125
[TBL] [Abstract][Full Text] [Related]
9. Association between Regimen Composition and Treatment Response in Patients with Multidrug-Resistant Tuberculosis: A Prospective Cohort Study.
Yuen CM; Kurbatova EV; Tupasi T; Caoili JC; Van Der Walt M; Kvasnovsky C; Yagui M; Bayona J; Contreras C; Leimane V; Ershova J; Via LE; Kim H; Akksilp S; Kazennyy BY; Volchenkov GV; Jou R; Kliiman K; Demikhova OV; Vasilyeva IA; Dalton T; Cegielski JP
PLoS Med; 2015 Dec; 12(12):e1001932. PubMed ID: 26714320
[TBL] [Abstract][Full Text] [Related]
10. Comparative roles of moxifloxacin and levofloxacin in the treatment of pulmonary multidrug-resistant tuberculosis: a retrospective study.
Jiang RH; Xu HB; Li L
Int J Antimicrob Agents; 2013 Jul; 42(1):36-41. PubMed ID: 23582696
[TBL] [Abstract][Full Text] [Related]
11. Limited Effect of Later-Generation Fluoroquinolones in the Treatment of Ofloxacin-Resistant and Moxifloxacin-Susceptible Multidrug-Resistant Tuberculosis.
Lee H; Ahn S; Hwang NY; Jeon K; Kwon OJ; Huh HJ; Lee NY; Kim CK; Koh WJ
Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29203478
[TBL] [Abstract][Full Text] [Related]
12. Treatment of multidrug-resistant tuberculosis in Taiwan.
Suo J; Yu MC; Lee CN; Chiang CY; Lin TP
Chemotherapy; 1996; 42 Suppl 3():20-3; discussion 30-3. PubMed ID: 8980864
[TBL] [Abstract][Full Text] [Related]
13. Retrospective comparison of levofloxacin and moxifloxacin on multidrug-resistant tuberculosis treatment outcomes.
Lee J; Lee CH; Kim DK; Yoon HI; Kim JY; Lee SM; Yang SC; Lee JH; Yoo CG; Lee CT; Chung HS; Kim YW; Han SK; Yim JJ
Korean J Intern Med; 2011 Jun; 26(2):153-9. PubMed ID: 21716591
[TBL] [Abstract][Full Text] [Related]
14. [The combination of amoxicillin-clavulanic acid and ofloxacin in the treatment of multidrug-resistant Mycobacterium tuberculosis].
Iwanaga T; Yokota K; Kishikawa R; Ikeda T; Tsurutani H; Hirose T; Nishima S
Kekkaku; 1997 Jan; 72(1):9-13. PubMed ID: 9038010
[TBL] [Abstract][Full Text] [Related]
15. The treatment of multidrug-resistant tuberculosis in Turkey.
Tahaoğlu K; Törün T; Sevim T; Ataç G; Kir A; Karasulu L; Ozmen I; Kapakli N
N Engl J Med; 2001 Jul; 345(3):170-4. PubMed ID: 11463011
[TBL] [Abstract][Full Text] [Related]
16. Treatment of multidrug-resistant tuberculosis in Thailand.
Maranetra KN
Chemotherapy; 1996; 42 Suppl 3():10-5; discussion 30-3. PubMed ID: 8980862
[TBL] [Abstract][Full Text] [Related]
17. Pulmonary resection combined with isoniazid- and rifampin-based drug therapy for patients with multidrug-resistant and extensively drug-resistant tuberculosis.
Park SK; Kim JH; Kang H; Cho JS; Smego RA
Int J Infect Dis; 2009 Mar; 13(2):170-5. PubMed ID: 18768342
[TBL] [Abstract][Full Text] [Related]
18. A controlled study of rifabutin and an uncontrolled study of ofloxacin in the retreatment of patients with pulmonary tuberculosis resistant to isoniazid, streptomycin and rifampicin. Hong Kong Chest Service/British Medical Research Council.
Tuber Lung Dis; 1992 Feb; 73(1):59-67. PubMed ID: 1326349
[TBL] [Abstract][Full Text] [Related]
19. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis.
Dawson R; Diacon AH; Everitt D; van Niekerk C; Donald PR; Burger DA; Schall R; Spigelman M; Conradie A; Eisenach K; Venter A; Ive P; Page-Shipp L; Variava E; Reither K; Ntinginya NE; Pym A; von Groote-Bidlingmaier F; Mendel CM
Lancet; 2015 May; 385(9979):1738-1747. PubMed ID: 25795076
[TBL] [Abstract][Full Text] [Related]
20. Time to sputum culture conversion in multidrug-resistant tuberculosis: predictors and relationship to treatment outcome.
Holtz TH; Sternberg M; Kammerer S; Laserson KF; Riekstina V; Zarovska E; Skripconoka V; Wells CD; Leimane V
Ann Intern Med; 2006 May; 144(9):650-9. PubMed ID: 16670134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
